Nuclear Medicine Imaging Equipment MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy ConfigurationBy End UserBy Component
Full title & scope — all 5 axes with their segments
Nuclear Medicine Imaging Equipment Market Size, Share & Industry Analysis, By Type (Full Ring PET Scanners, Partial Ring PET Scanners), By Application (Oncology, Cardiology, Others), By Configuration (PET/CT Hybrid Systems, Standalone PET Systems, PET/MRI Hybrid Systems), By End User (Hospitals, Diagnostic Imaging Centers, Academic & Research Institutes), By Component (Systems, Software & Reconstruction Solutions, Services & Maintenance), and Regional Forecast, 2026-2034
How the estimates were built: data sources, modelling approach and validation steps.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
The market is built upward from the number of nuclear medicine imaging systems installed each year, split by ring configuration and hybrid type, multiplied against average selling prices for new placements and replacement units at each configuration. Radiopharmaceutical dose volumes and reimbursement-coded procedure counts are used to cross-check installed-base utilization assumptions. This bottom-up build is then checked against disclosed imaging-equipment segment revenue reported by major manufacturers and against customs data for PET and SPECT system shipments under the applicable harmonized trade codes. Where the two diverge, the unit volume or price assumption feeding the bottom-up build is corrected rather than the disclosed revenue figure.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Primary research targets procurement and capital-equipment decision-makers inside hospital and diagnostic-imaging-center radiology departments, together with service and maintenance contract managers who track total cost of ownership across the installed base. Regulatory affairs staff at equipment manufacturers are consulted on approval timelines for new scanner configurations and radiopharmaceutical-compatible systems in each jurisdiction. Group purchasing organization and tender-office contacts are included where public procurement drives a meaningful share of placements. Sampling weights the United States, Germany, Japan and China, reflecting where installed-base scale and near-term placement volume are both concentrated, while adding contacts in Gulf and Southeast Asian markets where new imaging capacity is being built out.
Desk research draws on the FDA 510(k) clearance database for PET and SPECT system models, the EU's MDR conformity registers for CE-marked imaging equipment, and national health-ministry registries that publish installed PET/CT and SPECT/CT unit counts, including OECD health equipment statistics for cross-country comparison. Customs data under the harmonized code covering medical imaging apparatus is used to track cross-border equipment shipments. Nuclear regulatory authority registers of licensed cyclotron and radiopharmacy facilities inform radioisotope supply-side assumptions. Manufacturer annual reports and investor disclosures for imaging-equipment segments are used to size company-level revenue for the top-down check.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast is built from the expected replacement timing of the current installed base, the pace at which new PET tracers beyond FDG-18 move from approval into routine ordering, and the rate at which reimbursement coverage for PET-guided oncology staging expands in markets where it is not yet universal. Near-term years are adjusted to normalize for a scan-volume backlog that built up during prior service disruptions and is now working through the system rather than representing a permanent step-change in demand. The forecast holds if cancer screening volumes continue rising and if capital budgets for imaging equipment are not constrained by broader healthcare spending cuts.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Forecast outputs are back-tested against the market's own recorded 2020-2024 growth to confirm the model reproduces historical movement before it is extended forward. Segment share shifts, including the pace at which hybrid PET/MRI systems gain share from PET/CT, are reviewed against clinical adoption patterns reported by radiology specialists rather than accepted from the volume model alone. Sensitivities are tested for a radioisotope supply disruption that delays procedure volumes and for slower-than-modeled reimbursement expansion in markets where PET-guided oncology staging is not yet standard practice, and the resulting range is compared against the base forecast before it is finalized.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
Confidence is highest for installed-base and replacement-cycle estimates in the United States, Germany and Japan, where PET/CT ordering and reimbursement patterns are well documented. It is lower for adoption curves in emerging Asia Pacific and Latin American markets, where public installed-base counts are incomplete, and for the pace of PET/MRI uptake specifically, which is thin enough in several markets to require analogue-based estimation. A radioisotope supply disruption or an unexpected reimbursement policy reversal in a major market would be the most likely reasons to revise this forecast materially.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Nuclear Medicine Imaging Equipment Market projected to reach?
USD 14.31 Billion by 2034, CAGR 8.51%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 38% of global revenue through 2034.
05Which segment leads the market?
Full Ring PET Scanners is the largest line by type, at 68% of revenue in 2025.
06Who are the key companies profiled?
Digirad Corp. (US), Philips Healthcare (US), GE Healthcare Plc (UK), Mediso Medical Imaging Systems (Hungary), Siemens Healthineers (Germany), Positron Corporation (US). Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.